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Genetic predisposition of nuclear factor-kappa B (NF-kB)-
signaling pathways linking inﬂammation to hepatitis B virus
(HBV)-induced hepatocellular carcinoma (HCC) remains unre-
solved. We conducted a case–control study to determine the asso-
ciations of the polymorphisms within the promoter regions of
NFKB1 encoding NF-kB1 and NFKBIA encoding IkappaBalpha
with the development of HCC. A total of 404 healthy controls, 482
non-HCC subjects with HBVinfection and 202 patients with HCC
were included. NFKB1 294ATTG2 allele and GG allele in the 3#-
untranslated region of NFKBIA were more prevalent in HCC
patients than in the healthy controls. NFKBIA 2826CT and
NFKBIA 2881AG allelic carriages were more prevalent in HCC
patients than in the non-HCC subjects with HBV infection.
The estimated haplotype frequency of NFKBIA promoter
2881G2826T2519C was signiﬁcantly higher in the patients with
HCC than in the HBV-infected subjects without HCC (odds
ratio 5 3.142, P 5 0.002). As compared with the HBV-infected
subjects without HCC, NFKBIA 2826 T and NFKBIA 2881AG
allelic carriages were only associated with HCC risk in the
subjects with HBV genotype C. The association of NFKBIA
2881AG allelic carriage with HCC risk was not affected by liver
cirrhosis (LC) status, alanine aminotransferase level and hepatitis
B e antigen status. By multivariate regression analysis, NFKB1
294ATTG2, NFKBIA 2826T, NFKBIA 2881AG and HBV geno-
type C were independently associated with an increased risk of
HCC. In conclusion, NFKB1 294ATTG2 allele and haplotype
2881G2826T2519C in NFKBIA promoter were associated with
hepatocarcinogenesis. NFKBIA 2826Tand 2881AG were associ-
ated with the risk of HCC in the subjects infected with HBV
genotype C.
Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common cancer
worldwide and the third most common cause of cancer mortality. Most
HCC cases (.80%) occur in either Eastern Asia or sub-Saharan Africa
(1). Major risk factors for the development of HCC are chronic in-
fection with hepatitis B virus (HBV) or hepatitis C virus (HCV), liver
cirrhosis (LC), exposure to aﬂatoxin B1 and diabetes. It has been esti-
mated that 80% of HCC worldwide is etiologically associated with
HBV (2). Expression of hepatitis B e antigen (HBeAg) and a high
serumlevelofHBV (i.e.aviralload 10 000copies/ml)are associated
with an increased risk of HCC (3,4). HBV genotype C, genotype mix-
ture and viral mutations in the PreS, basal core promoter and enhancer
IIregionsof HBVare alsoassociatedwithanincreased riskofHCC (5–
7). HCC is widely accepted to be the outcome of chronic inﬂammation.
However, molecular mechanisms linking chronic inﬂammation to
HBV-induced hepatocarcinogenesis remain largely unresolved.
Activation of nuclear factor-kappa B (NF-jB), a hallmark of in-
ﬂammatory response that is frequently detected in tumors, may con-
stitute a missing link between inﬂammation and cancer (8,9). NF-jB
was originally identiﬁed as a nuclear factor speciﬁc to B cells bound
to the B site of the j-light chain gene enhancer. NF-jB is a hetero-
dimer in Rel family with ﬁve members: RelA, RelB, c-Rel, p50/105
(NF-jB1) and p52/p100, and the dimeric form of NF-jB p50/RelA is
the most common form. NF-jB has a central role in coordinating the
expression of a wide variety of genes that control innate and adaptive
immune responses and also has a critical role in cancer development
and progression (10). Recent studies have provided a causal link
between constitutive activation of NF-jB and liver neoplastic pro-
gression and have demonstrated that NF-jB is essential for promoting
inﬂammation-associated liver cancer and plays important roles in
hepatic inﬂammation, ﬁbrosis and the development of HCC—a pro-
cess called the ‘inﬂammation-ﬁbrosis-cancer axis’ (8,11–13). In nor-
mal cells, NF-jB is inactivated in the cytoplasm by binding to its
inhibitors, IjB. When IjB proteins are phosphorylated and degraded,
NF-jB is subsequently released and further translocated into the nu-
cleus, where the gene transcription is initiated (14). The IjB family
includes IkappaBalpha (IjBa), IjBb,IjBc,I jBd,I jBe,I jBf,I jB-R,
Bcl-3, p100 and p105 that are all constitutively expressed except for
IjBa, which is inducibly expressed. IjBa is a classic form of the IjB
family that can be found in cytoplasm and nucleus (15).
Allelic variants in human genome are probably to affect hepatitis
B progression after infection and are associated with poor prognosis
of chronic HBV infection. Several single-nucleotide polymorphisms
(SNPs) or haplotypes have reportedly been associated with an
increased or reduced risk of HCC occurrence in patients with HBV
infection (16,17). Polymorphic variations in the promoter regions
of NF-jB1 gene NFKB1 and IjBa gene NFKBIA and in the 3#-
untranslated region (3#-UTR) of NFKBIA were associated with the
risks of Hodgkin lymphoma, multiple myeloma, breast cancer, pros-
tate cancer, gastric cancer, colorectal cancer and melanoma (18–24).
Kim et al. (25) sequenced six exons and introns including  1000
promoter region of NFKBIA from 16 healthy volunteers and identiﬁed
10 polymorphisms. Six of 10 polymorphisms including two SNPs
( 673 A.T and  642 C.T) in the promoter region were selected
for HCC association study. They could not ﬁnd any signiﬁcant asso-
ciation of NFKBIA variants with the development of HCC among
chronic hepatitis B (CHB) patients. Except Kim’s study, there are
no report focusing on the association of the polymorphisms of NFKB1
and NFKBIA and the development of HCC. In this study, we evaluated
the associations of the polymorphisms of NFKB1 and NFKBIA with
the development of HCC as compared with either healthy controls
without HBV infection or HBV-infected subjects without HCC. To
our knowledge, it is the ﬁrst study that clearly demonstrates signiﬁ-
cant associations of the NFKB1 and NFKBIA polymorphisms with
HBV-induced hepatocarcinogenesis.
Abbreviations: ALT, alanine aminotransferase; AOR, adjusted odds ratios;
ASC, asymptomatic hepatitis B surface antigen carriers; CHB, chronic hepatitis
B; CI, conﬁdence intervals; HBeAg, hepatitis B e antigen; HBV, Hepatitis B
virus;HCC, hepatocellularcarcinoma;IjBa, IkappaBalpha;LC, liver cirrhosis;
NF-jB, nuclear factor-kappa B; PCR, polymerase chain reaction; SNP, single-
nucleotide polymorphism; 3#-UTR, 3#-untranslated region; WT, wild type.
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Clinical data
The study involved 404 HBV-infected patients treated at the ﬁrst and third
afﬁliated hospitals of this university from October 2006 to October 2008, 404
healthy controls without HBV infection from the physical examination center
of the First afﬁliated hospital from January 2007 to October 2008 and 280
asymptomatic hepatitis B surface antigen carriers (ASCs) recruited in an ep-
idemiological surveyfrom September to December 2006. All participants were
ethic Chinese. Diagnostic criteria of ASCs, the patients with CHB and the
patients with HCC, and exclusion criteria of the subjects were as described
previously (6). Only newly diagnosed HCC patients were included; patients
with a prior history of HCC or other cancers were excluded. LC was diagnosed
by using a Philips iU22 scanner (Philips Medical Systems, Best, The Nether-
lands) equipped with a 2–4 MHz variable convex probe. The ultrasonography
scoring system consisting of liver surface, parenchyma, vascular structure and
splenic size was used to describe the existence and severity of cirrhosis. The
scores ranged from four for a normal liver to 11 for advanced cirrhosis (26). A
score of eight or more was used as the cutoff point for HBV-related ultraso-
nographic cirrhosis. In addition to ultrasonographic ﬁndings, esophageal of
gastric varices, low platelet count and cirrhotic complications such as ascites
or encephalopathy were used for the diagnosis of clinical cirrhosis. The study
protocol conformed to the 1975 Declaration of Helsinki and was approved by
the ethics committees of the institutions,and aninformed consentwasobtained
from each participant.
Examination of HBV serological parameters
Before any treatment, 5 ml fasting blood was split into two blood collection
tubes with or without anticoagulant. The serum was separated by centrifuga-
tion at 4C and stored in a sterile tube at  80C within 4 h of sample
collection. Serological testing for hepatitis B surface antigen, HBeAg, alpha-
fetoprotein and liver function examination including alanine aminotransferase
(ALT) was performed as described previously (6). Upper limit of normal ALT
was 45 U/l. HBV DNA concentration was measured in the LightCyclerTM480
(Roche,Basel,Switzerland)usingquantitativeHBVpolymerasechainreaction
(PCR) ﬂuorescence diagnostic kits (Fuxun Diagnostics, Shanghai, China). The
kit has a certiﬁed lower limit of detection of 500 copies/ml. HBV genotype and
subgenotype were determined by a multiplex PCR assay (6,27).
SNP analysis
Genomic DNA was extracted from a 200 ll peripheral blood sample using
a QIAamp blood kit (QIAGEN, Hilden, Germany) according to the manufac-
turer’s instructions. Genotyping for the polymorphisms of NFKB1  94 ins/del
ATTG (rs 28720239), NFKBIA 3#-UTR A/G (rs 57898959), NFKBIA  519
C/T (rs 2233408),NFKBIA 826 C/T (rs 2233406)and NFKBIA 881 A/G (rs
3138053) was conducted using PCR–restriction fragment length polymor-
phism method. Primers for NFKB1  94 were 5#-TGGGCACAAGTCGTT-
TATGA-3# and 5#-CTGGAGCCGGTAGGGAAG-3#, amplifying a fragment
of 281 bps or 285 bps (23). Primers for NFKBIA 3#-UTR were 5#-
GGCTGAAAGAACATGGACTTG-3# and 5#-GTACACCATTTACAGGAG-
GG-3# that amplify a fragment of 424 bps (23). Primers for NFKBIA  519
C/T were 5#-GCTTTCACAACTTCTACCTG-3# and 5#-AGAGTGGAAAT-
GATGGCTG-3#, which amplify a fragment of 188 bps (24). Primers for
NFKBIA  826 C/T and  881 A/G were 5#-GGTCCTTAAGGTCCAATCG-3#
and 5#-GTTGTGGATACCTTGCACTA-3# (underlined, mismatched nucleo-
tide), which amplify a fragment of 200 bps (28). PCR was performed in 25 ll
mixture containing 50–100 ng DNA, 1  PCR buffer, 1 U Taq polymerase
(TaKaRa Biotechnology, Dalian, China), 0.5 lM each primer (synthesized
by Sangon Biotechnology, Shanghai, China) and 0.25 mM deoxynucleoside
triphosphate (TaKaRa Biotechnology). The ampliﬁcation was performed with
annealing temperature of 60C( NFKB1  94 or NFKBIA 3#-UTR) or 55C
(NFKBIA  519 or NFKBIA  826 and  881) for 30 s for 35 cycles by using an
Autorisierter thermocycler (Eppendorf AG, Humburg, Germany). The PCR
product of NFKB1  94 was digested with Van91 I (New England Biolabs,
Ipswitch, MA) at 37C for 18 h. The PCR product of NFKBIA 3#-UTR was
digested with HaeIII (TaKaRa) at 37C for 6 h. The PCR product of NFKBIA
 519 wasdigestedwithMnlI(NewEnglandBiolabs)at37C for6 h.The PCR
product of NFKBIA  826 was digested with XspI (TaKaRa) at 37C for 8 h,
whereas that of NFKBIA  881 was digested with TspRI (New England Biol-
abs) at 65C for 5 h. Both the PCR and restriction products were visualized in
2% agarose gel with 0.2 lg/ml ethidium bromide, together with the DNA
ladders, as shown in supplementary Figure 1 (available at Carcinogenesis
Online). Genotypes of NFKB1 polymorphisms were distinguished as wild type
(WT) (281 bps, ATTG1/ATTG1), heterozygote (ATTG1/ATTG2) and poly-
morphic homozygote (45 and 240 bps, ATTG2/ATTG2). Genotypes of
NFKBIA 3#-UTR polymorphisms were determined as WT (424 bps, AA),
heterozygote (AG) and polymorphic homozygote (108 and 316 bps, GG).
Genotypes of NFKBIA  519 polymorphisms were determined as WT (188
bps, CC), heterozygote (CT) and polymorphic homozygote (121 and 67 bps,
TT). Genotypes of NFKBIA  826 polymorphisms were determined as WT
(200 bps, CC), heterozygote (CT) and polymorphic homozygote (180 and 20
bps, TT). Genotypes of NFKBIA  881 polymorphisms were determined as
WT (200 bps, AA), heterozygote (200, 129 and 71 bps, AG).
Statistical analysis
The frequencies of all SNPs in health controls were tested for conformation to
Hardy–Weinberg equilibrium online (http://ihg.gsf.de/ihg/snps.htm1). Statisti-
cal analyses were performed using the Statistical Program for Social Sciences
(SPSS15.0 for Windows, SPSS, Chicago, IL). Categorical variables, like the
frequencies of SNPs and HBV genotypes, were tested by v2 test. Continuous
variables, like serum viral load and ALT level with skewed distribution, were
adjusted to normal distribution by transformation into logarithmic function and
then tested by Student’s t-test. To determine the factors contributing indepen-
dentlytoHCC,forward stepwise multivariateregression analysis(Pentry 5 0.05,
Premoval 5 0.10) was performed to obtain the adjusted odds ratios (AOR) of
polymorphisms for HCC risk and their 95% conﬁdence intervals (CI). The
estimated haplotype frequencies were determined by the estimating haplotype-
frequencies program (http://linkage.rockefeller.edu/soft/). A P value of ,0.05
was considered as statistically signiﬁcant. All statistical tests were two sided.
Results
The characteristics of the participants are presented in Table I.
Healthy controls without HBV infection, the patients with LC and
those with CHB were age and sex matched to the patients with
HCC. The patients with HCC were signiﬁcantly older and there were
higher proportion of men than ASCs. HBV genotype C (C2, 95.5%)
was more frequent in the patients with HCC than in the HBV-infected
participants without HCC (P , 0.001). Serum viral load of HBV was
signiﬁcantly higher in the HBV-infected participants without HCC
than in the patients with HCC, and the same were true for the fre-
quencies of HBeAg seropositivities and ALT levels.
Genotype data of all loci in the healthy controls were conformed to
Hardy–Weinberg equilibrium (P . 0.05 for each). Genotype data of
NFKB1  94, NFKBIA 3#-UTR and NFKBIA  826, except NFKBIA
 519 and NFKBIA  881, in the non-HCC patients with HBV infec-
tion did not conformed to Hardy–Weinberg equilibrium (Table II).
After being adjusted with age and sex, NFKB1  94 ATTG2/ATTG2
allelic carriage was more prevalent in the patients with HCC than in
the patients with CHB (41.1 versus 28.2%, AOR 5 2.17, 95% CI:
1.26–3.75, P 5 0.006), and the same was true for NFKBIA  881AG
allele (18.8 versus 6.9%, AOR 5 3.288, 95%CI: 1.71–6.33,
P , 0.001). As compared with ASCs, NFKBIA 3#-UTR GG allelic
carriage was signiﬁcantly associated with an increased risk of HCC
(32.2 versus 13.6%, AOR 5 2.44, 95%CI: 1.36–4.36, P 5 0.003)
after the adjustment with age and sex, and the same were true for
NFKBIA  826T (CTþTT) (26.2 versus 15.7%, AOR 5 2.19,
95%CI: 1.29–3.71, P 5 0.003) and NFKBIA  881AG alleles (18.8
versus 6.8%, AOR 5 3.20, 95%CI: 1.63–6.28, P 5 0.001). Interest-
ingly, we also found that NFKB1  94ATTG2 allelic carriage
(ATTG1/ATTG2þ ATTG2/ATTG2) was more prevalent in ASCs than
in the healthy controls (77.9 versus 69.3%, OR 5 1.670, 95%CI:
1.10–2.52, P 5 0.016). Table II shows the frequencies of all poly-
morphisms in the healthy controls and the HBV-infected patients with
and without HCC. As compared with the age-, sex-matched healthy
controls, NFKB1  94ATTG2 and NFKBIA 3#-UTR GG alleles were
more prevalent in the HBV-infected patients with HCC. NFKB1
 94ATTG2, NFKBIA  826CT and NFKBIA  881AG allelic car-
riages were more prevalent in the HBV-infected patients with HCC
than in the HBV-infected subjects without HCC.
The HBV-infected subjects were stratiﬁed into sex- or age-matched
groups. In women, NFKB1  94ATTG2, NFKBIA  826T and
NFKBIA  881G allelic carriages were signiﬁcantly associated with
the risk of HCC, as compared with the HBV-infected subjects without
HCC. In men, NFKBIA  881AG allelic carriage was signiﬁcantly
associated with an increased risk of HCC, as compared with the
HBV-infected subjects without HCC. In those ,53 years (average
age of the HBV-infected patients with HCC), NFKBIA  826T and
IkappaBalpha gene promoter polymorphisms and HCC
1917NFKBIA  881AG allelic carriages were signiﬁcantly associated with
the risk of HCC, as compared with the HBV-infected subjects without
HCC. In those at the age of  53 years, NFKBIA  881AG allelic
carriage was signiﬁcantly associated with an increased risk of HCC,
as compared with the HBV-infected subjects without HCC. The re-
sults are presented in the supplementary Table I and II (available at
Carcinogenesis Online), respectively.
We stratiﬁed the HBV-infected subjects into HBeAg-positive and
HBeAg-negative groups and then evaluated the association of the
polymorphisms with the development of HCC between the HCC pa-
tients with HBV infection and the non-HCC patients with HBV in-
fection. NFKBIA  881AG allelic carriage was associated with an
increased risk of HCC, either in HBeAg-positive group (22.9 versus
8.1%, OR 5 3.36, 95% CI: 1.46–7.75, P 5 0.003) or in HBeAg-
negative group (17.5 versus 5.9%, OR 5 3.42, 95% CI: 1.78–6.57,
P 5 0.000). We then stratiﬁed the HBV-infected subjects into normal
ALT (,45 U/l) and abnormal ( 45U/l) groups and evaluated the
association of the polymorphisms with the development of HCC
Table II. The frequencies of the polymorphisms at NFKB1  94 and NFKBIA 3#-UTR,  519,  826 or  881 in the participants
Polymorphisms (accession code) Alleles Healthy
controls
a
Non-HCC
with HBV
infection
a
HCC with
HBV
infection
a
AOR1 (95% CI) OR2 (95% CI) AOR2 (95% CI)
NFKB1  94 (rs28720239,
ATTG1 . ATTG2)
ATTG1/ATTG1 124 (30.7) 111 (24.1) 35 (17.3) 1.00 1.00
ATTG1/ATTG2 183 (45.3) 192 (41.7) 84 (41.6) 1.60 (1.01–2.53) 1.39 (0.88–2.19) 1.30 (0.80–2.10)
ATTG2/ATTG2 97 (24.0) 157 (34.1) 83 (41.1) 3.01 (1.87–4.85) 1.68 (1.05–2.67) 1.62 (1.00–2.64)
ATTG2 (ATTG1/ATTG2þ
ATTG2/ATTG2)
280 (69.3) 349 (75.8) 167 (82.7) 2.09 (1.37–3.19) 1.52 (0.99–2.32) 1.44 (0.93–2.25)
HWE P value
b 0.07 0.00
NFKBIA 3#-UTR (rs57898959,
A.G)
AA 138 (34.2) 186 (38.6) 70 (34.7) 1.00 1.00 1.00
AG 185 (45.8) 193 (40.0) 67 (33.2) 0.71 (0.47–1.06) 0.92 (0.62–1.36) 1.01 (0.67–1.53)
GG 81 (20.0) 103 (21.4) 55 (32.2) 1.61 (1.04–2.50) 1.68 (1.11–2.54) 1.49 (0.96–2.31)
G( A G þGG) 266 (65.8) 296 (61.4) 122 (65.4) 0.98 (0.68–1.39) 1.19 (0.84–1.67) 1.19 (0.83–1.71)
HWE P value
b 0.19 0.00
NFKBIA  519 (rs2233408,
C.T)
CC 321 (79.5) 368 (77.8) 162 (80.2) 1.00 1.00 1.00
CT 74 (18.3) 95 (20.1) 31 (15.3) 0.84 (0.53–1.33) 0.74 (0.48–1.16) 0.80 (0.50–1.28)
TT 9 (2.2) 10 (2.1) 9 (4.5) 1.98 (0.77–5.09) 2.04 (0.82–5.13) 1.64 (0.62–4.34)
T (CTþ TT) 83 (20.5) 105 (22.2) 40 (19.8) 0.96 (0.63–1.47) 0.87 (0.58–1.30) 0.89 (0.58–1.38)
HWE P value
b 0.06 0.19
NFKBIA  826 (rs2233406,
C.T)
CC 291 (72.0) 394 (81.7) 149 (73.8) 1.00 1.00 1.00
CT 105 (26.0) 76 (15.8) 52 (25.7) 0.98 (0.66–1.44) 1.81 (1.21–2.70) 1.89 (1.24–2.89)
TT 8 (2.0) 12 (2.5) 1 (0.5) 0.25 (0.03–2.00) 0.22 (0.03–1.71) 0.25 (0.03–2.01)
T (CTþ TT) 113 (28.0) 88 (18.3) 53 (26.2) 0.92 (0.63–1.35) 1.59 (1.08–2.35) 1.67 (1.11–2.53)
HWE P value
b 0.68 0.00
NFKBIA  881 (rs3138053,
A.G)
AA 331 (81.9) 449 (93.2) 164 (81.2) 1.00 1.00 1.00
AG 73 (18.1) 33 (6.8) 38 (18.8) 1.06 (0.69–1.64) 3.15 (1.91–5.20) 3.32 (1.95–5.65)
G G 000N D N D N D
HWE P value
b 0.06 1.00
AOR, odds ratio adjusted by age and sex; AOR1: healthy controls versus HCC with HBV infection; OR2 and AOR2: non-HCC with HBV infection versus HCC
with HBV infection; HWE, Hardy–Weinberg equilibrium; ND, no data.
aData were presented as n (%).
bSigniﬁcance probability determined by HWE test.
Table I. Characteristics of study subjects and their association with HCC
Characteristic Healthy controls
(N 5 404)
Non-HCC subjects with HBV infection (N 5 482) HCC patients with
HBV infection (N 5 202)
P value
ASC (n 5 280) CHB (n 5 110) LC (n 5 92)
Sex (male) 318 (78.7) 160 (57.1) 87 (79.1) 72 (78.3) 159 (78.7) 0.001
a
Age (year) 52.0 ± 9.61 43.7 ± 7.94 50.1 ± 12.28 50.5 ± 8.46 52.9 ± 9.76 0.000
a
Genotype
B ND 87 (31.1) 22 (21.8) 15 (17.9) 11 (5.8) 0.000
b
C ND 180 (64.3) 79 (78.2) 69 (82.1) 175 (91.6) ,0.01
c
Others ND 13 (4.6) ND ND 5 (2.6)
HBeAg
Positive ND 129 (46.1) 40 (36.4) 40 (43.5) 48 (23.8) 0.018
d
Negative ND 151 (53.9) 70 (63.6) 52 (56.5) 154 (76.2) 0.000
e
HBV DNA (Log10 copies/ml) ND ND 4.70 ± 1.67 4.17 ± 1.35 3.92 ± 1.17 0.000
f
ALT (Log10 U/l) ND ND 2.09 ± 0.48 1.85 ± 0.49 1.69 ± 0.31 ,0.01
c
Data shown as N (%), except age, ALT and HBV DNA; ND, no data.
aBetween ASC and HCC.
bBetween ASC and HCC.
cBetween HCC and CHB and between HCC and LC.
dBetween CHB and HCC.
eBetween HCC and ASC and between HCC and LC.
fBetween CHB and HCC.
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1918between the HCC patients with HBV infection and the non-HCC
patients with HBV infection. NFKBIA  881AG allelic carriage was
signiﬁcantly associated with an increased risk of HCC either in nor-
mal ALT group or in abnormal ALT group. NFKB1  94ATTG2,
NFKBIA 3#-UTR and NFKBIA  826T allelic carriages were signiﬁ-
cantly associated with the risk of HCC in normal ALT group, as
shown in the supplementary Table III (available at Carcinogenesis
Online).
We stratiﬁed the HBV-infected subjects into HBV genotype B- and
HBV genotype C-infected groups. After the adjustment with age and
sex, NFKBIA  826T and NFKBIA  881AG allelic carriages were
signiﬁcantly associated with the risk of HCC in the groups infected
with HBV genotype C, as compared with the HBV genotype C-
infected subjects without HCC (Table III).
We also found that the estimated haplotype frequency of NFKBIA
promoter  881G 826T 519C was signiﬁcantly higher in the pa-
tients with HCC than in the HBV-infected subjects without HCC
(Table IV).
There were no signiﬁcant differences in the frequencies of the
polymorphisms in all loci between the non-HCC patients with and
without LC, and the same was true for the difference between HCC
patients with and without LC. The frequency of NFKBIA  881AG
allele was signiﬁcantly higher in the patients with HCC than in those
without HCC, regardless of LC status (Figure 1). As compared with
the non-HCC patients with LC, the HCC patients had signiﬁ-
cantly higher frequencies of NFKBIA  881AG (18.8 versus 6.5%,
OR 5 3.32, 95% CI: 1.35–8.17, P 5 0.006) and NFKB1  94ATTG2
alleles (82.7 versus 71.7%, OR 5 1.88, 95% CI: 1.05–3.36,
P 5 0.032).
Independent factors contributing to HCC were evaluated in the
forward stepwise multivariate regression analysis (Table V). NFKB1
 94ATTG2 allelic carriage was independently associated with an
increased risk of HCC, as compared with the healthy controls. Age,
male, NFKBIA  816T allelic carriage and HBV genotype C were
independently associated with an increased risk of HCC, whereas
NFKBIA  519T allelic carriage was inversely associated with an in-
creased risk of HCC, if ASCs were used as controls. NFKB1
 94ATTG2 allele, NFKBIA  881AG allele and HBV genotype C
were independently associated with an increased risk of HCC if the
patients with CHB and those with LC served as controls. NFKB1
 94ATTG2 allelic carriage and NFKBIA  881AG allelic carriage
and genotype C were independently associated with increased risks
of HCC if combining ASCs, the patients with CHB and those with LC
as controls (supplementary Table IV is available at Carcinogenesis
Online).
Discussion
This study ﬁrstly demonstrated that the ATTG2 (ATTG1/ATTG2 þ
ATTG2/ATTG2) allelic carriage at  94 site of NFKB1 promoter sig-
niﬁcantly increased the risk of HCC either compared with the healthy
controls(Table II) orcompared withthe patientswith CHB after being
adjusted with age and sex. This study also revealed that NFKB1
 94ATTG2 allelic carriage was more prevalent in ASCs than in the
healthy controls (OR 5 1.67; 95% CI: 1.10–2.52) and more frequent
in the HBV-infected patients without HCC than in the healthy controls
(Table II), indicating that NFKB1  94ATTG2 allelic carriage might
also contribute to the risk of becoming chronic HBV infection. AOR
of the ATTG2 allele for HCC was higher in HCC versus the healthy
controls than in HCC versus CHBþLC (Table V). NFKB1
 94ATTG2 allelic carriage was independently associated with an
increased risk of HCC in the multivariate analysis using ASCs, the
patients with CHB and those with LC as controls (supplementary
Table IV is available at Carcinogenesis Online). Based on these ob-
servations, we hypothesize that NFKB1  94ATTG2 allelic carriage
might play a role from HBV chronic infection to HBV-induced hep-
atocarcinogenesis. Insertion/deletion of ATTG at  94 site of NFKB1
promoter is a functional NFKB1 polymorphism. The ATTG insertion
at the NFKB1 promoter signiﬁcantly increased the promoter activity,
as demonstrated by the promoter-luciferase reporter assay in transient
transfection and differential nuclear protein binding assays (29), in-
dicating that the individuals with the ATTG2 allele usually had higher
levels of NFKB1 transcript and further increase in production of NF-
jB protein. Thus, NFKB1  94ATTG2 allelic carriage-associated up-
regulation of NF-jB1 might play a role from chronic inﬂammation to
hepatocarcinogenesis caused by HBV chronic infection.
In this study, NFKBIA promoter polymorphisms were selected
based on their frequency determined in a preliminary screening of
200 normal subjects. The polymorphism at position  881 was further
selected based on potential functional effects due to their location
within transcription factor binding sites (http://www.cbrc.jp/research/
db/TFSEARCH.html). From this website and literature (30), we
created schematic diagrams to show several known transcription fac-
tor binding sites in NFkB1 and NFkBIA promoters (supplementary
Figure 2 is available at Carcinogenesis Online). The  881 locus is
within a consensus binding site (TAAA/TNTAGGTCA) for the
Table III. Association of the polymorphisms with the development of HCC in different HBV genotype groups
Polymorphism HBV genotype B HBV genotype C
Non-HCC
a HCC
a AOR (95% CI) Non-HCC
a HCC
a AOR (95% CI)
NFKB1  94
ATTG1/ATTG1 29 (24.8) 3 (27.3) 1.00 78 (24.8) 32 (18.3) 1.00
ATTG2 (ATTG1/ATTG2þATTG2/ATTG2) 88 (75.2) 8 (72.7) 0.747 (0.18–3.11) 236 (75.2) 143 (81.7) 1.46 (0.90–2.37)
NFKBIA 3#-UTR
AA 51 (41.1) 3 (27.3) 1.00 123 (37.5) 60 (34.3) 1.00
G( A G þGG) 73 (59.8) 8 (72.7) 2.05 (0.50–8.37) 205 (62.5) 115 (65.7) 1.13 (0.76–1.70)
NFKBIA  519
CC 101 (82.8) 11 (100.0) 1.00 250 (77.9) 142 (81.1) 1.00
T (CTþTT) 21 (17.2) 0 ND 71 (22.1) 33 (18.9) 0.87 (0.53–1.42)
NFKBIA  826
CC 104 (83.9) 9 (81.8) 1.00 267 (81.4) 129 (73.7) 1.00
T (CTþTT) 20 (16.1) 2 (18.2) 1.13 (0.22–5.74) 61 (18.6) 46 (26.3) 1.71 (1.07–2.73)
b
NFKBIA  881
AA 115 (92.7) 10 (90.9) 1.00 308 (93.9) 142 (81.1) 1.00
AG 9 (7.3) 1 (9.1) 1.15 (0.13–10.41) 20 (6.1) 33 (18.9) 4.02 (2.14–7.59)
c
AOR, odd ratio adjusted by age and sex; ND, no data.
aData were presented as n (%).
bP 5 0.024.
cP 5 0.000.
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NFKBIA  881G allelic carriage was an independent risk factor of
HCC, especially in the subjects infected with HBV genotype C. Al-
though there is not direct evidence showing that the  881G at the
promoter of NFKBIA decreases the promoter activity, indirect eviden-
ces indicate this possibility. For instance, NF-jB expression was twice
as high in the patients with sarcoidosis compared with the control
subjects, whereas the  881G allelic carriage and  826T allelic car-
riage were more prevalent in sarcoidosis than in the controls (31),
indicating that the  881G and  826T allelic carriages might be
associated with an increased activity of NF-jB. Since IkBa is an
absolute requirement for normal termination of the NF-jB response
(15), NFKBIA  881G and  826Tallelic carriages are therefore spec-
ulated to retard efﬁcient IjBa expression. NFKBIA  881G might
alter the binding ability of retinoic acid-related orphan receptor a,
a group of transcriptional factors with potential roles in osteoporosis,
autoimmune diseases and cancer (30), and contribute to hepatocarci-
nogenesis. This study found that NFKBIA  881 G and NFKBIA  826
Tallelic carriages were only associated with HCC in patients infected
with HBV genotype C (Table III). We speculate that the large HBV
surface protein and the X protein of genotype C might involve in this
process. The PreS2 domain of the large HBV surface protein is able to
activate a variety of promoter elements including NF-jB (32),
whereas our recent meta-analysis have shown that viral mutations
in PreS region are signiﬁcantly higher in HBV genotype C than in
genotype B during HBV-induced hepatocarcinogenesis (7). HBV X
protein is able to activate NF-jB by directly interacting with IjBa at
amino acids 249–253 of IjBa in the C-terminal part of the sixth
ankyrin repeat (33), while nucleotide change of codon 38 in the X
gene of HBV genotype C is independently associated with the de-
velopment of HCC (34). The large HBV surface protein and the X
protein of genotype C might speciﬁcally activate important transcrip-
tional factors in NF-jB-signaling pathways. Moreover, genotype C
products, e.g. X protein, might be able to bind NFKBIA  881G and
Table IV. The estimated haplotype frequencies of NFKBIA promoter
polymorphisms in the HBV-infected patients with HCC and the HBV-
infected subjects without HCC
NFKBIA promoter
haplotype
HCC
(N 5 202)
Non-HCC
(N 5 482)
OR (95% CI) P value
 881A 826C 519C 0.765 0.792 0.863 (0.582–1.280) 0.464
 881A 826C 519T 0.100 0.106 0.929 (0.538–1.602) 0.790
 881A 826T 519C 0.036 0.060 0.561 (0.242–1.302) 0.173
 881A 826T 519T 0.007 0.009 —
a —
a
 881G 826C 519C 0.003 0.004 —
a —
a
 881G 826C 519T 0.000 0.002 —
a —
a
 881G 826T 519C 0.076 0.025 3.142 (1.443–6.838) 0.002
 881G 826T 519T 0.016 0.003 —
a —
a
aOR and P value were not calculated due to small size of case number.
Fig. 1. NFKBIA  881AG allelic carriage was signiﬁcantly associated with
HCC as compared with non-HCC patients with HBVinfection, regardless of
LC state.
Table V. Multivariate regression analysis for factors independently associated with the risk of HCC
Variable HCC versus healthy controls HCC versus ASC HCC versus (CHBþLC)
AOR (95% CI) P AOR (95% CI) P AOR (95% CI) P
Age NS 1.12 (1.09–1.15) 0.000 NS
Sex
Female 1.00
Male NS 3.86 (2.23–6.69) 0.000 NS
NFKB1  94
ATTG1/ATTG1 1.00 1.00
ATTG2 (ATTG1/ATTG2þ ATTG2/ATTG2) 2.11 (1.39–3.22) 0.000 NS 1.84 (1.05–3.24) 0.034
NFKBIA  519
CC 1.00
T (CTþTT) NS 0.52 (0.28–0.96) 0.038 NS
NFKBIA  826
CC 1.00
T (CTþTT) NS 2.74 (1.48–5.08) 0.001 NS
NFKBIA  881
AA 1.00
AG NS NS 3.53 (1.54–8.08) 0.003
HBV genotype
B ND 1.00 1.00
C ND ND 10.43 (4.75–22.88) 0.000 4.01 (1.80–8.92) 0.001
HBeAg
Negative ND 1.00 1.00
Positive ND ND 0.39 (0.23–0.65) 0.000 0.50 (0.30–0.85) 0.010
ALT (Log10 U/l) ND ND ND 0.18 (0.10–0.33) 0.000
ND, no data; NS, no statistical signiﬁcance.
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speculations remain to be investigated in future. In this study, multi-
variate analysis showed that NFKBIA  519T allelic carriage was in-
versely associated with HCC risk, whereas NFKBIA  881G and
NFKBIA  826Tallelic carriages were independently associated with
an increased risk of HCC, as compared with the HBV-infected non-
HCC subjects with or without clinical symptoms (Table V). These
results were consistent with the observation that the estimated haplo-
type frequency of NFKBIA promoter  881G 826T 519C was sig-
niﬁcantly higher in the patients with HCC than in the subjects without
HCC (Table IV). The polymorphisms in NFKBIA promoter may also
affect the binding of other unknown transcription factors. Alteration
of one or more of these transcription factor binding sites could reduce
the levels of IjBa expression, increase NK-jB activity and contribute
to HBV-induced hepatocarcinogenesis.
This study also showed that no signiﬁcant differences in the
frequencies of polymorphisms in all loci were found between the
patients with and without LC and NFKBIA  881G allelic carriage
was associated with an increased risk of HCC regardless of LC status,
indicating that the polymorphisms were not associated with cirrhosis.
Since NF-jB plays important roles in the ‘inﬂammation-ﬁbrosis-can-
cer axis’ (13), the role of IjBa on HBV-induced hepatocarcinogenesis
may be not limited to NK-jB regulation.
HBV genotype C, elevated ALT, high viral load of HBV and
HBeAg positivity have been demonstrated to increase the risk of
HCC (4,5,35). In this study, however, elevated ALT, viral load and
HBeAg were inversely associated with the development of HCC, even
in age-, gender-matched groups. This difference is possibly due to
different study design and different study population recruited. In
prospective studies, ALT, HBV viral load and HBeAg have been
proved to be risk factors for HCC because these data are usually
collected at the beginning of cohort establishment. Because viral load
and HBeAg change dramatically during HBV-induced hepatocarcino-
genesis (6), it is difﬁcult to draw the same conclusion in prevalence
case–control study (36). This study recruited the hospitalized patients
with CHB and those with LC whose clinical symptoms and/or syn-
dromes were usually severe. HBV-infected patients with severe symp-
toms usually accompany with high ALT level and high viral load.
Nevertheless, the associations of the polymorphisms on the develop-
ment of HCC should be reliable in this case–control study because the
polymorphisms are germ line transmitted and do not change during
HBV-induced hepatocarcinogenesis.
In conclusion, NFKB1  94ATTG2, NFKBIA  826T and
NFKBIA  881G allelic carriages and HBV genotype C were in-
dependently associated with an increased risk of HCC, whereas
NFKBIA  519T allelic carriage was inversely associated with an
increased risk of HCC. The haplotype  881G 826T 519C in
NFKBIA promoter were associated with HBV-induced hepatocarci-
nogenesis. NFKBIA  826T and NFKBIA  881G allelic carriages
were associated with the risk of HCC in the subjects infected with
HBV genotype C.
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